Latest Factor VIII Stories
WAYNE, N.J., Aug. 7 /PRNewswire/ -- Today, Bayer HealthCare Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved a 3000 IU (international unit) vial size of Kogenate(R) FS, antihemophilic factor (recombinant).
BOSTON, July 15 /PRNewswire/ -- Bayer HealthCare announced today the recipients of the 2009 World Federation of Hemophilia's International Hemophilia Nursing Fellowship.
LAGUNA NIGUEL, Calif., July 14 /PRNewswire/ -- Inspiration Biopharmaceuticals today announced the presentation of positive preclinical safety, toxicology and preliminary pharmacokinetic data on its lead product, IB1001, a novel recombinant Factor IX product to treat patients with hemophilia B.
WAYNE, N.J., July 9 /PRNewswire/ -- Today, Bayer HealthCare Pharmaceuticals launched the BayCuff(TM) self-infusion training program, an educational initiative designed to make infusion of recombinant factor VIII easier for both patients with hemophilia A and for their caregivers.
BERKELEY, Calif., April 17 /PRNewswire/ -- In recognition of the 20th anniversary of World Hemophilia Day, Bayer HealthCare reaffirmed its commitment to the global hemophilia community by pledging euro 250,000 to the World Federation of Hemophilia (WFH).
New RNA therapy reversed hemophilia in mice GAITHERSBURG, Md., April 6 /PRNewswire/ -- VIRxSYS Corporation announced today the publication of a new research article, "Trans-splicing into Highly Abundant Albumin Transcripts for Production of Therapeutic Proteins In Vivo," in the journal Molecular Therapy.
NEW YORK, Feb. 19 /PRNewswire/ -- On Friday, February 13, 2009, Anna G. Eshoo (D-CA) and Jim Langevin (D-RI), along with Senators Byron Dorgan (D-ND) and Olympia Snowe (R-ME) introduced the Health Insurance Coverage Protection Act (H.R. 1085; S442).
IB1001, an Intravenous Recombinant Factor IX (rFIX) Product for the Treatment of Hemophilia B LAGUNA NIGUEL, Calif., Feb.
Researchers have made several, subtle changes in the structure of a key protein, dramatically increasing its ability to drive blood clotting, according to a study published in a December edition of the Journal of Thrombosis and Haemostasis.
- A person in a secondary role, specifically the second most important character (after the protagonist).